Clinical Trials Sponsored by EUSA Pharma

Total 9100 results

Chugai Pharma USA

Completed

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

Atherosclerosis | Coronary Restenosis | Graft Occlusion, Vascular

United States
Chugai Pharma USA

Completed

An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

Breast Cancer | Breast Neoplasms | Metastasis

United States
Chugai Pharma USA

Completed

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Gastroparesis

United States
Teikoku Pharma USA, Inc.

Not yet recruiting

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Agitation
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Teikoku Pharma USA, Inc.

Recruiting

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (DMT2111)

Pain, Postoperative

United States
Meiji Pharma USA Inc.

Completed

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Teikoku Pharma USA, Inc.

Unknown

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

Pain, Postoperative

United States
Fidia Pharma USA Inc.

Completed

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

Knee Osteoarthritis | Osteoarthritis, Knee | Patellofemoral Osteoarthritis

United States
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Horizon Pharma USA, Inc.

Recruiting

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

United States
Teikoku Pharma USA, Inc.

Completed

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System (DTP-System)

Irritation/Irritant

United States
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Teikoku Pharma USA, Inc.

Completed

Flurbiprofen Tape for Treatment of Chronic Low Back Pain (LBP)

Chronic Low Back Pain

United States
Teikoku Pharma USA, Inc.

Completed

Study of a New Dressing for Use With Topical Medications

Psoriasis

United States
Astellas Pharma Inc
Ono Pharma USA Inc

Completed

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Bone Diseases | Osteoporosis | Osteoporosis, Postmenopausal

Japan
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Astellas Pharma Inc
Ajinomoto USA, INC.

Completed

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus | Diabetes Mellitus, Type II

Japan
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
University of Birmingham
Roche Pharma AG; Cancer Research UK; Imagine for Margo; EUSA Pharma, Inc.

Active, not recruiting

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (BEACON)

Neuroblastoma

France, Austria, Belgium, Denmark, Ireland, Italy, Spain, Switzerland, United Kingdom, Netherlands
National Jewish Health
Fidia Pharma USA Inc.

Recruiting

Synovial Fluid Biomarkers Pre and Post Hymovis Knee Injection

Knee Osteoarthritis

United States
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Kidney Cancer | Renal Cancer

Japan
University of Pittsburgh
Horizon Pharma USA, Inc.

Recruiting

Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community

Undiagnosed Disease

United States
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States, Canada, Italy, Finland
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Phase I Biomarker Study (BMS-936558)

Renal Cell Carcinoma

United States, France, Spain
H. Lee Moffitt Cancer Center and Research Institute
EUSA Pharma, Inc.

Recruiting

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Large Granular Lymphocyte Leukemia

United States
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (LIGHT-NING)

Non-Small Cell Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Cancer of Head and Neck | Cancer of the Head | Cancer of the Neck

Japan
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
German Breast Group
Roche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor Pharma

Completed

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH; Trio Clinical Research, LLC, Raleigh, USA; NuCara Pharmacy... and other collaborators

Completed

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Asthma

United States

3

Subscribe